Updates in uricase therapy for gout
Exogenous uricases available and those under development are discussed, focusing on immunomodulation and anti-inflammatory prophylaxis to reduce flares, prevent antidrug antibody formation and infusion reactions, and mitigate loss of efficacy in patients with uncontrolled gout needing uricase replacement therapy.
Authors
- Dan Kaufmann (ORCID: https://orcid.org/0000-0001-9836-1370)
- Naomi Schlesinger (ORCID: https://orcid.org/0000-0002-1558-1202)
Institutions
- University of Utah (US)
- Center for Rheumatology (US)
Publication Details
- Journal
- Current Opinion in Rheumatology
- Published
- 2025-09-03
- DOI
- https://doi.org/10.1097/bor.0000000000001122
- Citations
- 2
- Primary Topic
- Gout, Hyperuricemia, Uric Acid
- Type
- article
- Field-Weighted Citation Impact
- 2.86